Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
G. Michael Landis is Chief Financial Officer at Polaryx Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 20, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
1
Companies involved
1
1 buy, median −5.5 pts vs S&P 500, beat it 0 of 1 time.
Average −5.5 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Feb 20, 2026 to Feb 20, 2026, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-16 would be worth $717 today ($1K put in); the same in the S&P 500 (SPY): $1.1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Feb 18, 2026Bought~$8Kdisclosed Feb 20
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
As of the latest filing on , G. Michael Landis reported holding 228,225 shares of Polaryx Therapeutics (PLYX), worth about $381K at the last close of $2 (Nov 16, 2026). In the last 12 months, G. Michael Landis bought $8K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Polaryx Therapeutics PLYX | 228,225 | 228K direct | $2 | $381K | Feb 18, 2026 |
Is this G. Michael Landis’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
G. Michael Landis bought shares on the open market in 2026.
G. Michael Landis reported 1 open-market purchase and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $8K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Feb 18, 2026, G. Michael Landis reported holding 228,225 shares of Polaryx Therapeutics (PLYX). At the last close of $2 on Nov 16, 2026, that is about $381K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, G. Michael Landis reported 1 open-market purchase worth $8K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
G. Michael Landis bought shares on the open market in 2026.
In SEC filings since 2026: the latest open-market purchase is from 2026; no open-market sale is on record.
Polaryx Therapeutics (PLYX), from 2026 to 2026: 1 purchase and 0 sales.
G. Michael Landis reported 1 open-market purchase and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.